Roche Reports Positive Phase III Results for Eye Drug Vamikibart and FDA Filing Acceptance

Key Facts

1Roche reported positive Phase III trial results for its eye drug vamikibart.

2The US FDA has accepted the Biologics License Application (BLA) for the drug.

Roche reported positive Phase III trial results for its eye drug vamikibart. According to Zacks, the US FDA has accepted the Biologics License Application (BLA) for the drug following clinical data that showed sustained vision improvements and reduced retreatment needs.

RHHVF closed at $434.14 on October 9, 2026, with the stock reaching a day high of $434.14 and a low of $427.1 during that session. These regulatory milestones follow the drug meeting its primary endpoints in clinical trials with a favorable safety profile, moving the treatment closer to commercial approval in the United States.